Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more
Evoke Pharma Inc (EVOK) - Total Liabilities
Latest total liabilities as of September 2025: $12.29 Million USD
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has total liabilities worth $12.29 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evoke Pharma Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Evoke Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Evoke Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ananda Development Public Company Limited
BK:ANAN
|
Thailand | ฿17.27 Billion |
|
Imaflex Inc
PINK:IFLXF
|
USA | $25.95 Million |
|
Thai Rayon Public Company Limited
BK:TR
|
Thailand | ฿6.98 Billion |
|
Bakrie Sumatera Plantations
JK:UNSP
|
Indonesia | Rp8.59 Trillion |
|
Scoda Tubes Limited
NSE:SCODATUBES
|
India | ₹3.34 Billion |
|
KNOREX LTD.
NYSE MKT:KNRX
|
USA | $9.78 Million |
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
USA | $57.94 Million |
|
Seyitler Kimya Sanayi AS
IS:SEYKM
|
Turkey | TL60.64 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Evoke Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evoke Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evoke Pharma Inc (2011–2024)
The table below shows the annual total liabilities of Evoke Pharma Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.48 Million | +8.63% |
| 2023-12-31 | $9.65 Million | +24.22% |
| 2022-12-31 | $7.77 Million | +10.67% |
| 2021-12-31 | $7.02 Million | -44.52% |
| 2020-12-31 | $12.65 Million | +527.70% |
| 2019-12-31 | $2.02 Million | +23.29% |
| 2018-12-31 | $1.63 Million | -71.70% |
| 2017-12-31 | $5.78 Million | +4.89% |
| 2016-12-31 | $5.51 Million | -9.24% |
| 2015-12-31 | $6.07 Million | -0.75% |
| 2014-12-31 | $6.11 Million | +60.73% |
| 2013-12-31 | $3.80 Million | -80.77% |
| 2012-12-31 | $19.78 Million | +6.55% |
| 2011-12-31 | $18.56 Million | -- |